Aaron Chang

Scientist

[Aaron Chang @A_YChang]

Excited to share our team's work developing a PD1-targeted-IL2 immunocytokine! https://t.co/vfEcZvPstq

[Thomas Gardner @TJJardinero]

Excited to share my work from @DASLab_MSKCC lab out today in @nchembio where we develop CAR-T cells that produce small molecule drugs at the tumor site. This is an exciting step forward in the utilization of engineered cells for drug delivery! https://t.co/zuR7qs2JIr

[Aaron Chang @A_YChang]

Excited to see this published! Fortunate to have worked with this amazing team while I was a postdoc at #Pfizer Former #PfizerProud
https://t.co/cLpdfG47Fh

[Aaron Chang @A_YChang]

Tyrosine kinase inhibitors are drugs that target specific Achilles heel's in cancers. Now we demonstrate that these inhibitors also make cancer cells present new antigens to the immune system!

[Scheinberg Lab @DASLab_MSKCC]

Excited to share our latest manuscript where we show a novel mechanism of HLA regulation, which leads to presentation of new (and potentially immunogenic!!) peptides https://t.co/kGtVBy7ncn

[Scheinberg Lab @DASLab_MSKCC]

Excited to share our latest manuscript where we show a novel mechanism of HLA regulation, which leads to presentation of new (and potentially immunogenic!!) peptides https://t.co/kGtVBy7ncn

[Aaron Chang @A_YChang]

#Immunotherapy #neoantigen

[Aaron Chang @A_YChang]

https://t.co/T8uREb8Lrt

Very cool to see this out! Fun to work on an interesting question of tumor neoantigen heterogeneity with @rongejman. What started as a "side-project" led to some interesting and unexpected results.

[Ron S. Gejman MD, PhD @rongejman]

One of my PhD papers is published today ⁦⁦@eLife⁩ ! I’ll write a thread about this story later, but one funny bit I’ll share now is that I got a mini heart attack every time we got an email about the manuscript because of “rejection” in the title. https://t.co/V9BUhjSjPE

[Aaron Chang @A_YChang]

Awesome work from the Brentjens lab team! Lets push what CAR-T's can do in solid tumors
https://t.co/oOrufckqQC

[Aaron Chang @A_YChang]

Proud to see this out! Grateful to this team that taught me my fundamental immunology. Read to learn about pDC functional and developmental abnormalities in chronic viral infections
https://t.co/DldawXcjhW

[Aaron Chang @A_YChang]

Preprint for a project that has been cooking in the lab! a mammalian cell-based system to determine cross-reactive targets of TCRs or TCR-based therapy agents. Enjoy! https://t.co/lBx9kjB6Ed

[Ron S. Gejman MD, PhD @rongejman]

Preprint is out! Fun to see an off-the-cuff idea turn into a manuscript + spawn (ongoing) projects. Thanks @A_YChang and other co-authors as well as @diegochowell for a careful read! Enjoy and contact us if you want to use the PresentER antigen minigenes! https://t.co/Mt1f0OaOPC

[Aaron Chang @A_YChang]

The latest work from the Scheinberg Lab: a TCR mimic antibody against an A*02/PRAME antigen: https://t.co/2psuIH3SpZ
#cancerimmunotherapy https://t.co/wEEDmmKyNp

[Ron S. Gejman MD, PhD @rongejman]

Check out our latest: a TCR mimic antibody against an A*02/PRAME antigen. @A_YChang https://t.co/hGlrUPFeDr #cancerimmunotherapy

[Aaron Chang @A_YChang]

TCR mimic antibodies for cancer therapy https://t.co/GKjmDfXT9e